David Dorsey, Principal, Tech Investment Team @OUP
David joined OUP in 2016. His focus areas are networks, wireless technology, signal processing, and machine learning. Prior to joining OUP, David was a lead engineer at Lockheed Martin, where he served as principal investigator for multiple DARPA/DoD programs providing unique solutions in RF spectrum operations. While at Lockheed’s Advanced Technology Laboratories, he collaborated with university labs and industry partners to design, develop, execute and pursue transition opportunities for early concept technologies.
Stephanie Stehman, Principal, Life Science Investment Team @OUP
Stephanie joined OUP in 2015 and focuses on investments in therapeutics, diagnostics, and medical devices across all stages of development. She led OUP’s investments in Landos Biopharma, Fortis Therapeutics, Pionyr Immunotherapeutics (acquired by Gilead), Modis Therapeutics (acquired by Zogenix), Cell Design Labs (acquired by Gilead), and others. Previously, Stephanie was with H.I.G. BioVentures, a venture capital firm that makes investments in the life sciences sector.